SOF PD-L1 delivers measurable improvements in cancer immunotherapy assessment
Trained with 1M+ cell annotations by 150+ pathologists worldwide, SOF PD-L1 generates analysis results that are close to the ground truth.
By generating objective results, SOF PD-L1 reduces interpretation discrepancy between pathologists, leading to more consistent diagnoses and treatment decisions.
Based on 96% accuracy, SOF PD-L1 finds 50% more patients eligible for immunotherapy compared to human-classified PD-L1(-) patient groups.
Advanced AI technologies for precise PD-L1 analysis
Detects tumor cell PD-L1 +/- and inflammatory cell PD-L1 +/- from whole slide images with high precision.
Calculates PD-L1 positive scores including TPS (Tumor Proportion Score) and CPS (Combined Positive Score).
Provides AI analysis results including PD-L1 TPS score and map within a comprehensive report.